Results 241 to 250 of about 2,480 (301)
Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 2004 Using a highly sensitive fluorimetric assay, significant levels of angiotensin I -converting enzyme-like activity (ACELA) were detected in a range of tissues (branchial heart, gill, kidney with associated vasculature and archinephric duct, liver, whole ...
Christopher S Cobb, Frank B Jensen
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Is the adrenal angiotensin receptor angiotensin II — or angiotensin III like?
Acta Endocrinologica, 1983Abstract. In order to determine whether the adrenal receptor is primarily directed at angiotensin II (All) or angiotensin III (AIII) the following in vitro experiments were performed examining aldosterone responsiveness in isolated glomerulosa cells.
L M, Braley +3 more
openaire +2 more sources
Angiotensin and angiotensin receptors in cartilaginous fishes
Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology, 2001In mammals, a principal bioactive component of the renin-angiotensin system (RAS), angiotensin II (ANG II), is known to be vasopressor, dipsogenic, a stimulant of adrenocortical secretion and to control glomerular and renal tubular function. Historically, a RAS analogous to that found in mammals was thought to have first evolved in the bony fishes ...
ANDERSON W. G +6 more
openaire +3 more sources
Conversion of Angiotensin I to Angiotensin II
Nature, 1967Results obtained with the blood bathed organ technique indicate that angiotensin I is converted rapidly to angiotensin II in the pulmonary circulation and not by an enzyme in the blood.
K K, Ng, J R, Vane
openaire +2 more sources
Angiotensin in atherosclerosis
Current Opinion in Nephrology and Hypertension, 2004While it is well established that angiotensin II promotes cardiovascular and renal disorders, recent evidence has indicated a pivotal role in atherosclerotic disease which is distinguished by the central abnormality of lipid accumulation within the vascular wall.Studies published in the last year show that angiotensin II activity is increased in ...
Valentina, Kon, Kathy, Jabs
openaire +2 more sources
Acta Physiologica Scandinavica, 1995
A brief account for the renal renin‐angiotensin system (RAS), its inhibitors and receptors, as for the presence of an intrinsic cerebral RAS is initially provided. The review is then focused upon the circumventricular organs as cerebral targets for blood‐borne angiotensin II (Ang II) and on centrally mediated Ang II effects.
B, Andersson, S, Eriksson, M, Rundgren
openaire +2 more sources
A brief account for the renal renin‐angiotensin system (RAS), its inhibitors and receptors, as for the presence of an intrinsic cerebral RAS is initially provided. The review is then focused upon the circumventricular organs as cerebral targets for blood‐borne angiotensin II (Ang II) and on centrally mediated Ang II effects.
B, Andersson, S, Eriksson, M, Rundgren
openaire +2 more sources
Human Leukocytes Contain Angiotensin I, Angiotensin II and Angiotensin Metabolites
International Archives of Allergy and Immunology, 2009Angiotensin I (ANG I) and angiotensin II (ANG II) were measured radioimmunologically in human leukocytes extracted with a mixture of acetone, 1N HCl and water (40:1:10 vol). The analytical recoveries of 125I-ANG I and 125I-ANGII, which were added prior to extraction, were 92.00 ± 3.I0 and 99.19 ± 0.91% (mean ± SEM; n = 12).
K, Hermann, J, Ring
openaire +2 more sources
Clinical and Experimental Pharmacology and Physiology, 1998
SUMMARY1. One of the most important issues in the field of hypertension research centres on the therapeutic use of inhibitors of the renin‐angiotensin system (RAS). Inhibitors of the RAS have potent anti‐hypertensive effects, even in experimental models of hypertension and in human essential hypertension, where the activity of the peripheral RAS is low
E H, Blaine +5 more
openaire +2 more sources
SUMMARY1. One of the most important issues in the field of hypertension research centres on the therapeutic use of inhibitors of the renin‐angiotensin system (RAS). Inhibitors of the RAS have potent anti‐hypertensive effects, even in experimental models of hypertension and in human essential hypertension, where the activity of the peripheral RAS is low
E H, Blaine +5 more
openaire +2 more sources